New high-performance chemistry combined with PCR-free DNBSEQ nanoarray platform delivers higher quality and more sequencing reads SAN JOSE, CA, Feb. 21, 2020– MGI, part of global genomics leader BGI Group, today announced the commercial availability of its sequencing instruments and reagent kits in the United States based on MGI’s innovative CoolMPS™sequencing chemistry, starting in April of this year. MGI is planning to roll out its G series DNBSEQ sequencers first in Q2 and then its...

The nucleic acid detection technology based on real-time fluorescent RT-PCR method has played an important role in the rapid identification and diagnosis of coronaviruses. However, to study the origin of coronaviruses, their evolution and pathogenic mechanisms, it is necessary to obtain complete viral genome information, which requires high-throughput sequencing and viral sequence assembly. In order to fully reveal the relevant features of the new coronavirus, MGI can provide integrated s...

Remote ultrasonic robot made by MGI On February 16th, the "Remote Ultrasound Robot" independently developed by MGI Remote Ultrasound Diagnostic System was delivered to Wuhan Huangpi Fangcai Hospital; on February 17, the remote ultrasonic robot was delivered to Lei Shenshan Hospital. As of February 18, all the remote ultrasound equipment headed to the epidemic area have completed the installation, commissioning and training, and quickly supported the ultrasound inspection work in the epide...

MGI, a member of global genomics leader BGI Group, has expanded its DNA sequencing and laboratory automation products available in Latin America, signing agreements with top distributors in Brazil, Argentina, Peru, Ecuador, Colombia and Mexico. Through these experienced partners, MGI will be able to immediately offer its products for the research, clinical/diagnostics and other markets. Distributors have acquired MGI sequencers and other instruments to offer local demonstrations and train...

The nucleic acid test of 2019-novel coronavirus (2019-nCoV, now was named as COVID-19 suggested by WHO) is an essential reference for clinical diagnosis and discharge of patients, and an important evidence for whom with close contact to confirmed case under quarantine to be released. The "Huo-Yan " laboratory with daily testing capacity of 10,000 samples can provide sufficient testing capabilities for Wuhan and surrounding cities, for the diagnosis of patients with fever, the screening of...

Since the outbreak of the novel coronavirus pneumonia, nucleic acid testing has been an important diagnostic basis for clinical diagnosis, release from isolation, and rehabilitation and discharge from hospital. With the further development of the epidemic situation, the anti-epidemic "battlefield" needs to face more complex areas and usage scenarios, and has further requirements for detection equipment and technology. In order to meet the needs of "mobile real-time detection,” MGI has ...